Hickory Asset Management Inc. Takes Position in Veeva Systems Inc. (NYSE:VEEV)

Hickory Asset Management Inc. acquired a new stake in shares of Veeva Systems Inc. (NYSE:VEEV) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 1,838 shares of the technology company’s stock, valued at approximately $386,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in VEEV. MassMutual Private Wealth & Trust FSB raised its position in shares of Veeva Systems by 72.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock valued at $25,000 after buying an additional 50 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC bought a new position in shares of Veeva Systems during the 3rd quarter valued at $26,000. True Wealth Design LLC grew its holdings in shares of Veeva Systems by 3,375.0% during the 3rd quarter. True Wealth Design LLC now owns 139 shares of the technology company’s stock valued at $29,000 after purchasing an additional 135 shares during the last quarter. Avion Wealth grew its holdings in shares of Veeva Systems by 635.0% during the 4th quarter. Avion Wealth now owns 147 shares of the technology company’s stock valued at $30,000 after purchasing an additional 127 shares during the last quarter. Finally, Retirement Wealth Solutions LLC bought a new position in shares of Veeva Systems during the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on VEEV. StockNews.com lowered shares of Veeva Systems from a “buy” rating to a “hold” rating in a report on Thursday, February 6th. Citigroup raised their price target on shares of Veeva Systems from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Morgan Stanley raised their price target on shares of Veeva Systems from $183.00 to $195.00 and gave the stock an “underweight” rating in a report on Tuesday, December 17th. Scotiabank raised their price target on shares of Veeva Systems from $235.00 to $240.00 and gave the stock a “sector perform” rating in a report on Friday, December 6th. Finally, Robert W. Baird raised their price target on shares of Veeva Systems from $275.00 to $283.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.96.

Insider Buying and Selling at Veeva Systems

In other news, SVP Jonathan Faddis sold 1,694 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $230.30, for a total value of $390,128.20. Following the completion of the sale, the senior vice president now owns 8,061 shares in the company, valued at approximately $1,856,448.30. This trade represents a 17.37 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is owned by company insiders.

Veeva Systems Stock Down 0.0 %

VEEV stock opened at $234.09 on Friday. Veeva Systems Inc. has a 52 week low of $170.25 and a 52 week high of $258.93. The company has a fifty day simple moving average of $224.80 and a two-hundred day simple moving average of $215.67. The firm has a market capitalization of $38.00 billion, a P/E ratio of 57.80, a price-to-earnings-growth ratio of 1.97 and a beta of 0.85.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.